These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 28329208)

  • 1. Differentiated Human Immunodeficiency Virus RNA Monitoring in Resource-Limited Settings: An Economic Analysis.
    Negoescu DM; Zhang Z; Bucher HC; Bendavid E;
    Clin Infect Dis; 2017 Jun; 64(12):1724-1730. PubMed ID: 28329208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis.
    Boyer S; March L; Kouanfack C; Laborde-Balen G; Marino P; Aghokeng AF; Mpoudi-Ngole E; Koulla-Shiro S; Delaporte E; Carrieri MP; Spire B; Laurent C; Moatti JP;
    Lancet Infect Dis; 2013 Jul; 13(7):577-86. PubMed ID: 23602084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.
    Mauskopf J; Brogan A; Martin S; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():83-105. PubMed ID: 21182346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of monitoring strategies for antiretroviral therapy of HIV infected patients in resource-limited settings: software tool.
    Estill J; Salazar-Vizcaya L; Blaser N; Egger M; Keiser O
    PLoS One; 2015; 10(3):e0119299. PubMed ID: 25793531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients.
    Kimmel AD; Goldie SJ; Walensky RP; Losina E; Weinstein MC; Paltiel AD; Zhang H; Freedberg KA;
    Antivir Ther; 2005; 10(1):41-52. PubMed ID: 15751762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies.
    Ouattara EN; Robine M; Eholié SP; MacLean RL; Moh R; Losina E; Gabillard D; Paltiel AD; Danel C; Walensky RP; Anglaret X; Freedberg KA
    Clin Infect Dis; 2016 Jun; 62(11):1454-1462. PubMed ID: 26936666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of ART in resource-limited countries.
    Loubiere S; Meiners C; Sloan C; Freedberg KA; Yazdanpanah Y
    Curr Opin HIV AIDS; 2010 May; 5(3):225-31. PubMed ID: 20539078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.
    Brogan A; Mauskopf J; Talbird SE; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():129-46. PubMed ID: 21182348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost effectiveness of antiretroviral treatment strategies in resource-limited settings.
    Bishai D; Colchero A; Durack DT
    AIDS; 2007 Jun; 21(10):1333-40. PubMed ID: 17545710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How do different eligibility guidelines for antiretroviral therapy affect the cost-effectiveness of routine viral load testing in sub-Saharan Africa?
    Scott Braithwaite R; Nucifora KA; Toohey C; Kessler J; Uhler LM; Mentor SM; Keebler D; Hallett T
    AIDS; 2014 Jan; 28 Suppl 1(0 1):S73-83. PubMed ID: 24468949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of point-of-care CD4+ and laboratory viral load in tailoring antiretroviral therapy monitoring strategies to resource limitations.
    Hyle EP; Jani IV; Rosettie KL; Wood R; Osher B; Resch S; Pei PP; Maggiore P; Freedberg KA; Peter T; Parker RA; Walensky RP
    AIDS; 2017 Sep; 31(15):2135-2145. PubMed ID: 28906279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of point-of-care viral load monitoring of antiretroviral therapy in resource-limited settings: mathematical modelling study.
    Estill J; Egger M; Blaser N; Vizcaya LS; Garone D; Wood R; Campbell J; Hallett TB; Keiser O;
    AIDS; 2013 Jun; 27(9):1483-92. PubMed ID: 23462219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
    Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
    Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
    Moeremans K; Hemmett L; Hjelmgren J; Allegri G; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():147-67. PubMed ID: 21182349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost Effectiveness of Potential ART Adherence Monitoring Interventions in Sub-Saharan Africa.
    Phillips AN; Cambiano V; Nakagawa F; Bansi-Matharu L; Sow PS; Ehrenkranz P; Ford D; Mugurungi O; Apollo T; Murungu J; Bangsberg DR; Revill P
    PLoS One; 2016; 11(12):e0167654. PubMed ID: 27977702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis.
    Bendavid E; Young SD; Katzenstein DA; Bayoumi AM; Sanders GD; Owens DK
    Arch Intern Med; 2008 Sep; 168(17):1910-8. PubMed ID: 18809819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models.
    Keebler D; Revill P; Braithwaite S; Phillips A; Blaser N; Borquez A; Cambiano V; Ciaranello A; Estill J; Gray R; Hill A; Keiser O; Kessler J; Menzies NA; Nucifora KA; Vizcaya LS; Walker S; Welte A; Easterbrook P; Doherty M; Hirnschall G; Hallett TB
    Lancet Glob Health; 2014 Jan; 2(1):e35-43. PubMed ID: 25104633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Benefits and Cost-Effectiveness of Laboratory Monitoring Strategies to Guide Antiretroviral Treatment Switching in India.
    Freedberg KA; Kumarasamy N; Borre ED; Ross EL; Mayer KH; Losina E; Swaminathan S; Flanigan TP; Walensky RP
    AIDS Res Hum Retroviruses; 2018 Jun; 34(6):486-497. PubMed ID: 29620932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of routine viral load monitoring in low- and middle-income countries: a systematic review.
    Barnabas RV; Revill P; Tan N; Phillips A
    J Int AIDS Soc; 2017 Nov; 20 Suppl 7(Suppl 7):. PubMed ID: 29171172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Optimizing resources to reduce costs to determine HIV viral load in limited resources settings].
    Girón-Callejas A; Mendizabal-Burastero R; Yax E; Martínez A; Mejía-Villatoro C
    Biomedica; 2017 Dec; 37(4):460-465. PubMed ID: 29373766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.